Emergent BioSolutions, Inc. (EBS)
6.23
+0.36
(+6.13%)
USD |
NYSE |
Sep 11, 16:00
6.25
+0.02
(+0.32%)
After-Hours: 20:00
Emergent BioSolutions Enterprise Value : 766.90M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 766.90M |
| September 10, 2026 | 748.43M |
| September 09, 2026 | 738.68M |
| September 08, 2026 | 755.10M |
| September 04, 2026 | 765.87M |
| September 03, 2026 | 766.90M |
| September 02, 2026 | 778.70M |
| September 01, 2026 | 766.39M |
| August 31, 2026 | 760.23M |
| August 28, 2026 | 750.48M |
| August 27, 2026 | 752.02M |
| August 26, 2026 | 753.56M |
| August 25, 2026 | 736.63M |
| August 24, 2026 | 713.03M |
| August 21, 2026 | 707.90M |
| August 20, 2026 | 694.57M |
| August 19, 2026 | 698.16M |
| August 18, 2026 | 686.36M |
| August 17, 2026 | 678.15M |
| August 14, 2026 | 682.77M |
| August 13, 2026 | 677.64M |
| August 12, 2026 | 680.72M |
| August 11, 2026 | 675.58M |
| August 10, 2026 | 676.61M |
| August 07, 2026 | 695.59M |
| Date | Value |
|---|---|
| August 06, 2026 | 719.70M |
| August 05, 2026 | 834.10M |
| August 04, 2026 | 835.64M |
| August 03, 2026 | 827.43M |
| July 31, 2026 | 817.69M |
| July 30, 2026 | 819.74M |
| July 29, 2026 | 824.36M |
| July 28, 2026 | 822.30M |
| July 27, 2026 | 823.33M |
| July 24, 2026 | 819.74M |
| July 23, 2026 | 832.05M |
| July 22, 2026 | 836.15M |
| July 21, 2026 | 839.74M |
| July 20, 2026 | 841.80M |
| July 17, 2026 | 838.72M |
| July 16, 2026 | 841.80M |
| July 15, 2026 | 852.06M |
| July 14, 2026 | 832.05M |
| July 13, 2026 | 858.21M |
| July 10, 2026 | 860.26M |
| July 09, 2026 | 866.93M |
| July 08, 2026 | 864.88M |
| July 07, 2026 | 872.58M |
| July 06, 2026 | 866.93M |
| July 02, 2026 | 872.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exelixis, Inc. | 13.29B |
| Capricor Therapeutics, Inc. | 339.48M |
| ADMA Biologics, Inc. | 2.148B |
| Akebia Therapeutics, Inc. | 312.17M |
| Arcutis Biotherapeutics, Inc. | 2.875B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -180.20M |
| Revenue (Quarterly) | 234.30M |
| Total Expenses (Quarterly) | 414.50M |
| EPS Diluted (Quarterly) | -3.492 |
| Gross Profit Margin (Quarterly) | 51.22% |
| Profit Margin (Quarterly) | -76.91% |
| Earnings Yield | -57.04% |
| Operating Earnings Yield | 40.51% |
| Normalized Earnings Yield | -7.368 |